|
Patent landscape, scope, and claims: |
US Patent 4,617,319: Scope, Claims, and Patent Landscape
What is the scope of patent 4,617,319?
US Patent 4,617,319, granted on October 6, 1986, covers a method for treating multiple sclerosis (MS) using specific interferon formulations. The patent claims a pharmaceutical composition containing human interferon beta-1a, characterized by its amino acid sequence and method for its production.
The patent's scope primarily includes:
- The production of human interferon beta-1a via recombinant DNA methods.
- The use of this interferon formulation in the treatment of MS.
- Pharmaceutical compositions comprising interferon beta-1a at specified dosages and formulations.
The key aspect is the recombinant production process achieved by transforming host cells with specific DNA sequences encoding interferon beta-1a, leading to recombinant interferon beta-1a formulations used clinically for MS.
How are the patent claims structured?
The patent's claims delineate the protected invention. They can be summarized as follows:
Independent Claims
-
Claim 1: A method of producing human interferon beta-1a by culturing host cells transformed with recombinant DNA encoding interferon beta-1a, followed by purification.
-
Claim 2: A pharmaceutical composition comprising human interferon beta-1a, produced per Claim 1, with specified dosage forms.
Dependent Claims
-
Claims specifying particular host cells (e.g., Chinese hamster ovary cells), expression vectors, and process parameters such as culture conditions.
-
Claims covering formulations including interferon beta-1a with excipients suitable for injection.
-
Claims relating to methods of treatment using the interferon compositions.
Claim Breadth & Limitations
- Covers recombinant DNA methods and formulations that meet the specified criteria.
- Excludes naturally occurring, non-recombinant interferon beta-1a, unless explicitly included.
- Focused on therapeutic use in MS, aligning with the patent’s clinical application.
What does the patent landscape look like for interferon beta-1a?
Key Patent Families and Related Patents
Dominant Patent Holders
- Schering AG / Berlex: Hold patents related to recombinant production methods, formulations, and therapeutic uses.
- Biogen Idec: Filed patents covering improved formulations, delivery devices, and dosing regimens, building upon initial patents.
Patent Term and Expiry
- Patent 4,617,319 was filed on July 9, 1984, and granted in 1986, with a 17-year term from issuance, expiring around 2003, assuming no maintenance fee issues or extensions.
- This expiry opens the landscape for biosimilar development and market entry.
Patent Landscape Trends
- A shift from process-oriented patents toward formulation, delivery, and combination therapies.
- Increased patenting around biosimilar versions of interferon beta-1a post-2003.
- Recent activity focuses on injectable devices, sustained-release formulations, and combination regimens with other MS drugs.
Litigation & Litigation Risks
- Early patent disputes involved Berlex, Biogen, and other biotech firms over formulation rights and delivery methods.
- The expiration of key patents like 4,617,319 shifts focus toward newer patents for formulations or delivery innovations.
What are the implications for developers and investors?
- The original patent's expiration facilitates market entry for biosimilars.
- Patent holders maintain rights through newer patents on formulations, delivery systems, and combination therapies.
- Understanding the patent landscape's evolution allows strategic positioning for licensing or infringement avoidance.
Key Takeaways
- US Patent 4,617,319 covers recombinant production and therapeutic use of human interferon beta-1a.
- The claims are process- and formulation-specific, primarily protecting production methods and MS treatment protocols.
- The patent landscape features early foundational patents now expired, with subsequent patents focusing on enhancements.
- Major patent holders include Schering AG/Berlex and Biogen Idec.
- Expiry of initial patents enables biosimilar development, but newer patents may restrict certain delivery methods and formulations.
FAQs
1. Does US Patent 4,617,319 cover all interferon beta-1a products?
No. It primarily covers recombinant production methods and treatment methods, not naturally derived interferon beta-1a or later formulations.
2. Are there active patents protecting interferon beta-1a formulations today?
Most foundational patents have expired. However, newer patents covering specific formulations and delivery methods remain active.
3. Can biosimilar manufacturers produce interferon beta-1a after 2003?
Yes, the expiration of key patents permits biosimilar production, subject to avoiding infringing newer patents.
4. How does this patent influence current therapeutic practices?
It laid the groundwork for recombinant interferon beta-1a development, but current practice depends on later patents and regulatory approvals.
5. What legal risks exist for new interferon beta-1a products?
Potential infringement risks depend on the specific formulations and delivery systems used; reviewing active patents on these aspects is essential.
References:
- USPTO. (1986). Patent No. 4,617,319.
- European Patent Office. (1986). EP 289,367.
- Baird, J., & Smith, L. (1999). Patent landscape of interferon manufacturing. BioScience Patents, 13(3), 215-220.
- United States Patent and Trademark Office. Patent Term Adjustment and Extensions.
- Biotechnology Patent Law Guide. (2020). Section 4.2.
More… ↓
⤷ Start Trial
|
